{"id":"W4400284560","doi":"10.3390/curroncol31070278","title":"Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Capecitabine; Oncology; Triple-negative breast cancer; Neoadjuvant therapy; Internal medicine; Pembrolizumab; Breast cancer; Immunotherapy; Disease; PARP inhibitor; Cancer; Poly ADP ribose polymerase","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002278662,0.0004394272,0.001096434,0.000707871,0.0002612384,0.001629324,0.0007366731,0.001037235,0.003517809],"category_scores_gemma":[0.003319521,0.0001527692,0.001018057,0.0007576152,0.0006113581,0.00189188,0.000677001,0.002055044,0.0005447167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009575731,"about_ca_system_score_gemma":0.002124305,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001030395,"about_ca_topic_score_gemma":0.003800696,"domain_scores_codex":[0.9991518,0.0003952315,0.000117657,0.0001104674,0.0001649544,0.00005977677],"domain_scores_gemma":[0.998396,0.00104741,0.0002190525,0.00002837141,0.0002484423,0.00006081446],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005005089,0.0001023911,0.0009701679,0.03898272,0.0004203392,0.0004563909,0.0003155625,0.001131637,0.001701178,0.01390379,0.02407916,0.9174362],"study_design_scores_gemma":[0.0002383047,0.0009539471,0.003087389,0.0369771,0.0009894103,0.001849083,0.0006010659,0.0007096066,0.001164315,0.01350835,0.9398596,0.00006183213],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009026164,0.991389,0.0003705069,0.005138374,0.000392768,0.00001580377,0.000034822,0.000007100284,0.001748998],"genre_scores_gemma":[0.01184888,0.9829816,0.0008716922,0.003034264,0.0006294027,0.00003775316,0.00006467017,0.000005157744,0.0005265237],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003517809,"threshold_uncertainty_score":0.01205081,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09949363293038195,"score_gpt":0.459674902024783,"score_spread":0.3601812690944011,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}